In Parts 1 and 2 of this series, we introduced the fundamentals of mesotherapy and explored the clinical process patients experience.
Now, in this final installment, we turn the spotlight to AesMed’s innovations—most notably, AGF39™ Cytokines Therapy—and share our mission for the future of alopecia treatment.
Innovation with AGF39™ Cytokines Therapy
At the heart of AesMed’s contribution to mesotherapy is AGF39™, a cytokine-rich therapeutic solution developed specifically for alopecia care.
How AGF39™ Works:
- Suppresses DHT-Induced Follicle Damage: Protects follicles from apoptosis caused by dihydrotestosterone (DHT).
- Activates Stem Cells: Stimulates the regeneration of follicle stem cells, helping dormant follicles re-enter the growth cycle.
- Normalizes the Hair Cycle: Extends the anagen (growth) phase while reducing premature shedding.
AGF39™ is more than just an add-on to mesotherapy—it is a scientifically validated solution that transforms each session into a targeted, regenerative treatment.
Holistic Approach: Daily + Clinical Care
AesMed believes alopecia treatment should not end at the clinic. To maximize outcomes, we combine professional in-clinic mesotherapy with daily scalp care products.
- Advance Follicle Shampoo (4th Generation):
Formulated with nonionic surfactant technology, it gently supports scalp health while remaining hypoallergenic and eco-friendly.
- Integration with Mesotherapy:
Using AGF39™ in mesotherapy alongside consistent home scalp care creates a synergistic effect, improving both immediate and long-term results.
This dual approach ensures patients benefit from professional precision while maintaining scalp balance at home.
Global Expansion of Hair Care
Since its first steps in 2020, the Hair Care Day Campaign has become a global symbol of alopecia awareness. AesMed continues to expand this movement in partnership with:
- Hair loss hospitals and clinics.
- Medical specialists and researchers.
- International partners in Japan, China, Türkiye, Malaysia, and Azerbaijan.
Looking ahead to 2026, AesMed aims to showcase these efforts at the World Congress for Hair Research (WCHR) in Seoul, positioning Hair Care Day and AGF39™ as part of the global conversation on hair loss solutions.
AesMed’s Mission and Vision
At AesMed, our mission is to deliver science-based, patient-centered treatments that improve quality of life for those suffering from alopecia. Our vision is to lead a future where:
- Alopecia is recognized and treated as a serious medical and social issue.
- Innovation like AGF39™ bridges the gap between advanced research and real patient outcomes.
- Global collaboration unites doctors, companies, and patients in shared purpose.
“We believe in more than treating hair loss—we believe in restoring confidence, dignity, and hope for patients worldwide.”
Key Takeaway
Mesotherapy, when powered by AesMed’s AGF39™ Cytokines Therapy, represents the third evolution in alopecia treatment—a shift from symptomatic management to cellular-level regeneration.
By combining clinical excellence with home care innovation, AesMed continues to redefine the future of hair and scalp health.
Stay tuned as we share more updates on our global initiatives and breakthroughs in alopecia care.
Learn more: www.aesmed.co.kr
